MAUNA KEA TECHNOLOGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4035 EUR | -0.86% |
|
-1.10% | -14.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 7.1M 7.7M | Sales 2025 * | 8.2M 8.89M | Capitalization | 25.05M 27.16M |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -9.76M | Net income 2025 * | -8M -8.68M | EV / Sales 2024 * | 8.73 x |
| Net Debt 2024 * | 36.9M 40.02M | Net Debt 2025 * | 45.2M 49.02M | EV / Sales 2025 * | 8.57 x |
| P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-2.39
x | Employees | 67 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mauna Kea Technologies
More press releases
More news
| 1 day | -0.98% | ||
| 1 week | -1.23% | ||
| Current month | +0.25% | ||
| 1 month | +2.28% | ||
| 3 months | -6.50% | ||
| 6 months | -12.39% | ||
| Current year | -14.44% |
1 week
0.40
0.41
1 month
0.380.42
Current year
0.340.52
1 year
0.340.77
3 years
0.341.33
5 years
0.342.37
10 years
0.3410.20
| Managers | Title | Age | Since |
|---|---|---|---|
Sacha Loiseau
CEO | Chief Executive Officer | - | 00-04-30 |
| Director of Finance/CFO | - | 23-06-12 | |
Nathalie Lecoq
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chris McFadden
BRD | Director/Board Member | - | 07-12-31 |
Sacha Loiseau
CEO | Chief Executive Officer | - | 00-04-30 |
Molly O'Neill
BRD | Director/Board Member | 60 | 18-01-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.4035 | -0.86% | 59 674 |
| 24-05-16 | 0.407 | +0.49% | 43,389 |
| 24-05-15 | 0.405 | -1.94% | 40,131 |
| 24-05-14 | 0.413 | +0.98% | 146,847 |
| 24-05-13 | 0.409 | +0.25% | 15,808 |
Real-time Euronext Paris, May 17, 2024 at 08:49 am EDT
More quotes
Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools. The group's products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. Net sales break down by activity as follows:
- sale of licenses (40.7%);
- sales of accessories (37.3%): mini-probes, software, etc.;
- sales of system (11.2%);
- services (10.8%).
Net sales are distributed geographically as follows: Europe/Middle East/Africa (15.5%), the United States and Canada (42.9%) and Asia (41.6%).
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.407
EUR
Average target price
2
EUR
Spread / Average Target
+391.40%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.44% | 27.23M | |
| -40.31% | 2.95B | |
| +18.54% | 1.88B | |
| -2.22% | 1.63B | |
| +34.26% | 1.34B | |
| -16.73% | 959M | |
| -22.64% | 888M | |
| +7.07% | 842M | |
| -25.66% | 623M | |
| +11.32% | 513M |
- Stock Market
- Equities
- ALMKT Stock
